The Medicines Co., based in New Jersey, said in a release it hosted a webcast March 17 featuring results from its ORION-1 Phase II study of inclisiran, the company’s PCSK9 synthesis inhibitor for the treatment of hypercholesterolemia.
The Late-Breaking Clinical Trials - Featured Clinical Research 1 session was presented at the American College of Cardiology’s 66th annual scientific session.
Those who joined the webcast included the management and product teams for inclisiran; ORION-1’s principal investigator Dr. Kausik K. Ray, professor of public health at Imperial College London; as well as Dr. John J.P. Kastelein, professor of medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam.
The webcast can be accessed at http://www.themedicinescompany.com/investors/events.
